阿美戈拉汀联合氨磺必利对阴性症状为主的精神分裂症患者神经营养因子的影响

Effect of amiagolatine combined with amisulpride on neurotrophic factors in schizophrenia patients with negative symptoms

目的探讨阿美戈拉汀联合氨磺必利治疗以阴性症状为主的精神分裂症患者的临床疗效及对神经营养因子(NT-3)、脑源性神经营养因子(BDNF)的影响。方法选取收治的80例以阴性症状为主的精神分裂症患者,将其按照随机数字法随机分为观察组和对照组,每组40例,两组均给予认知矫正疗法,对照组在此基础上给予氨磺必利进行治疗,观察组在此基础上给予阿美戈拉汀进行治疗,疗程为3个月,对治疗前后两组患者的阳性与阴性症状量表(PANSS)评分及阴性症状分量表(NEG)评分进行评价、采用WHO生存质量测定量表简表(WHOQOL-BREF)评估患者各领域生活质量,采用双任务研究范式对患者进行基于时间及基于事件前瞻记忆测试,并对两组治疗前后血清NT-3、BDNF进行检测。结果治疗后两组PANSS评分及NEG评分均显著下降(P<0.05),但观察组下降更明显(P<0.05)。治疗后两组基于时间前瞻记忆及基于事件前瞻记忆次数均显著下降(P<0.05),但观察组下降更为明显(P<0.05)。治疗后生理领域、心理领域、社会关系、环境领域生活质量评分均显著提高(P<0.05),但观察组提高更为明显(P<0.05)。治疗后两组NT-3、BDNF水平均显著上升(P<0.05),但观察组上升更为明显(P<0.05)。结论阿美戈拉汀联合氨磺必利能够起到协同作用,可明显地改善精神分裂症的阴性症状,提高患者生活质量水平,改善前瞻性记忆,提高患者血清神经营养因子NT-3和BDNF水平。

Objective To investigate the clinical efficacy of amiagolatine combined with amisulpride on the treatment of schizophrenia patients with negative symptoms and its effects on neurotrophic factor(NT-3)and brain-derived neurotrophic factor(BDNF).Methods Eighty schizophrenia patients with negative symptoms in our hospital were selected and randomly divided into the observation group and the control group(n=40).Patients in both groups received cognitive correction therapy.The control group received amisulpridetreatment,while the observation group received amiagolatine treatment for 3 months.In the two groups,indexes including the positive and negative symptom scale(PANSS)score,the negative symptom subscale(NEG)score,and the WHO quality of life measurement scale(WHOQOL-BREF)were used for assessment.The patients received time-based and event-based prospective memory tests.Serum NT-3 and BDNF were recorded before and after treatment.Results PANSS score and NEG score were significantly reduced after treatment(P<0.05),and the reduction was significantly more in the observation group(P<0.05).After treatment,the time-based memory and event-based memory were significantly reduced(P<0.05),and the reduction was significantly more in the observation group(P<0.05).After treatment,the life quality scores in physiological,psychological,social and environmental fields were all significantly increased(P<0.05),and the improvement in the observation group was significantly more(P<0.05).The levels of NT-3 and BDNF in the two groups were significantly increased after treatment(P<0.05),and the increase in the observation group was significantly more(P<0.05).Conclusion Amegolastine combined with amisulpride can synergistically improve the negative symptoms of schizophrenia,life quality,prospective memory,and serum neurotrophic factors NT-3 and BDNF levels.